MatsukiyoCocokara stock reports 14.9 percent profit growth

Published on 09/30/2026 at 08:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MatsukiyoCocokara posted JPY 148.65 billion in first-quarter net income on August 10, 2026. Fiscal 2027 guidance calls for JPY 1.155 trillion in sales.

Matsukiyo, JP3869010003, Illustration mit AI erstellt.

MatsukiyoCocokara stock is backed by first-quarter net income of JPY 14.87 billion, up 14.9 percent from the prior-year period. The result gives the Japanese drugstore operator a concrete earnings catalyst as its fiscal 2027 plan targets further growth.

First quarter delivers double-digit growth

According to Finance Limo on September 24, 2026, MatsukiyoCocokara reported first-quarter revenue of JPY 289.35 billion for the period ended June 30, 2026, up 5.7 percent year over year.

Operating profit reached JPY 21.49 billion, an 8.5 percent increase, while ordinary profit rose 8.8 percent to JPY 22.82 billion. Net income therefore grew faster than revenue, pointing to operating leverage in the opening quarter of fiscal 2027.

Annual guidance sets the next test

Finance Limo reported that management kept its fiscal 2027 forecast at JPY 1.155 trillion in revenue, JPY 87.50 billion in operating profit and JPY 59.00 billion in net income. The net income target is 5.8 percent above the fiscal 2026 result.

The same report puts the planned annual dividend at JPY 56.00 per share, including an interim payment of JPY 28.00. The September 30, 2026 record date makes the distribution schedule a direct near-term shareholder checkpoint.

Tokyo quote and valuation

Global Banking & Finance Review identifies MatsukiyoCocokara as ticker 3088 on the Tokyo Stock Exchange under ISIN JP3869010003. The latest structured quote showed JPY 2,430.50 at 3:09 p.m. JST on September 30, 2026, against a 52-week range of JPY 2,171.50 to JPY 3,044.00.

Market capitalization stood at JPY 956.0 billion on September 30, 2026. The combination of 5.7 percent first-quarter sales growth and 14.9 percent net income growth leaves execution against the full-year targets as the central investor measure.